- recruitingPHASE3
An Extension Study for Patients Previously Enrolled in Studies With Pelabresib
This study looks at the continued safety and benefit of a medicine called pelabresib for people with blood or solid cancers. It's for those who have used pelabresib before in other studies.
United States · Belgium · Italy - active not recruitingPHASE3
Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing
This study offers continued access to treatments like Avelumab for people who were in earlier Pfizer studies and are still benefiting. It focuses on several cancers and ensures ongoing care and tracking of their health.
United States · Australia · Belgium - ongoing, recruitingHuman Pharmacology (Phase I)- First administration to humans
A Phase 1a/1b Study Exploring the Safety and Tolerability of INCB081776 in Participants With Advanced Malignancies
This study is testing a new medicine called INCB081776 for people with advanced cancers. It's the very first time this medicine is being given to humans, so doctors are checking how safe it is and if it causes side effects.
Netherlands - recruitingPHASE1, PHASE2
BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)
This study is testing a new drug, BI-1808, by itself and with another medicine, pembrolizumab (Keytruda®), for people with advanced cancers. The goal is to see how safe the new drug is, what side effects it causes, and find the right dose for future studies.
United States · Denmark · Hungary - authorisedPhase I and Phase II (Integrated)- Other
A Multicenter, Open-label, Phase 1/2 Safety Run-in and Expansion Study of PM54 in Combination With Immunotherapy Evaluating Safety and Efficacy in Adult Participants who were Previously Treated for Advanced Malignancies
This study is testing a new medicine, PM54, alongside an existing treatment, pembrolizumab, for adults with advanced cancers. We want to see how safe this combination is and if it helps by shrinking tumours or stopping them from growing.
Spain - ongoing, recruitingHuman Pharmacology (Phase I)- First administration to humans
A First-in-Human Study to Evaluate the Safety and Anti-cancer Activity of the product FS120, which is an Antibody medication, to be administered alone or with Pembrolizumab in Subjects with Advanced Malignancies
This early study is looking at a new antibody medicine, FS120, for people with advanced cancers. Researchers want to see if it's safe and if it helps fight cancer, either alone or with another cancer drug called Pembrolizumab.
Spain